Table 1.
Comparison of demographic and clinical characteristics of the patients evaluated with OAS and GS. Statistical significance is indicated (P).
Table 2.
Skin test results to inhalant and food allergens in patients with OAS and GS. Statistical significance is indicated (P).
Figure 1.
ELISA results to allergens (Mal d 1, Mal d 2, rMal d 3, rMal d 4, rPru p 3, rBet v 1 and Pho d 2) in sera from patients with OAS (N = 35) and GS (N = 46) and a control group with tolerance to apple (N = 25).
(A) Results are expressed as individual O.D. values and median represented as a dotted line. (B) Results are expressed as the percentage of positive cases. (*p<0.05) represents a significant difference compared to healthy controls.
Table 3.
Percentages of ELISA positive cases combining allergens from LTP and profilin family in patients allergic to apple with OAS or GS.
Figure 2.
ELISA Inhibition results using rMal d 3 and rPru p 3 in the solid phase for a representative case from Group 1 with GS (A); Mal d 4 and Pho d 2 in a representative case from Group 2 with OAS (B) and a case with GS (C); and Mal d 3 and Pho d 2 in a representative case from Group 3 with OAS (D) and a case with GS (E).
Sera were preincubated with decreasing concentrations (20–0.2 µg/ml) of rMal d 3, rMal d 4, rPru p 3, and Pho d 2, before they were added to the solid phase. Results are expressed as percentage inhibition.
Figure 3.
ELISA Inhibition results using in the solid phase rMal d 1 (A) and rBet v 1 (B) with different concentrations (20–0.2 µg/ml) of rMal d 1, Mal d 2, rMal d 3, rMal d 4 and rBet v 1 in a representative OAS patient with high recognition of Betv1.